Idenix Pharma’s PULLBACK Deemed Overreaction and 4 Stock Analyses Not to Miss

Aeropostale, Inc. (NYSE:ARO) price target was reduced by Brean Murray after flat Q2 results. The firm lowered its estimates due to reduced guidance and competition in core basics. Brean Murray reiterated its Buy rating since it believes that Aeropostale is on the correct path to drive material upside when its business stabilizes.

Don’t Miss: Do Hedge Funds Still Have Faith in GOLD?

CME Group Inc. (NASDAQ:CME): According to UBS, CME Group and IntercontinentalExchange (NYSE:ICE) are the largest near-term beneficiaries of OTC derivatives reform and mandated clearing. The firm keeps its Buy ratings and increases CME Group’s price target to $69 from $60 and IntercontinentalExchange’s price target to $169 from $153.

Gap Inc. (NYSE:GPS) price target was increased by Susquehanna after it showed solid Q2 results due to improved product acceptance, solid comp increases, and raised regular price selling. Shares have a Positive rating.

Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) has been added to JPMorgan’s Analyst Focus List after the sell-off in shares yesterday but reduced its price target for the stock to $15 from $25. The firm believes that the 30 percent pullback yesterday is an overreaction, mentioning that cardiac and liver toxicity has not been seen for Idenix’s hepatitis C drug in the lab or in the clinic. JPMorgan states that Gilead (NASDAQ:GILD) is also on its Analyst Focus List.

Marvell Technology Group Ltd. (NASDAQ:MRVL) price target has been reduced by Susquehanna after showing weak Q2 results. The firm blamed a significant decline in mobile/wireless which causes some to question the sustainability of its handset business. Shares keep a Neutral rating.

Don’t Miss: Is Apple EXAGGERATING Samsung’s Success?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.